Navigation Links
American Oriental Bioengineering Reports Third Quarter 2009 Financial Results
Date:11/16/2009

477 Advertising 9,013,087 9,913,728 22,360,380 21,760,300 General and administrative 6,457,734 4,690,793 15,981,195 14,235,806 Depreciation and amortization 1,409,399 1,024,436 5,118,588 3,012,107 Total operating expenses 29,125,966 25,567,834 70,313,540 61,664,690 INCOME FROM OPERATIONS 15,005,195 21,623,708 43,861,587 51,899,372 EQUITY IN EARNINGS (LOSS) FROM UNCONSOLIDATED ENTITIES (563,608) 49,417 (299,072) (591,650) INTEREST INCOME (EXPENSE), NET (1,106,805) (1,143,013) (4,306,143) (1,156,782) OTHER (EXPENSE), NET (49,165) 91,986 (164,103) (264,515) INCOME BEFORE INCOME TAXES 13,285,617 20,622,098 39,092,269 49,886,425 INCOME TAXES 3,257,771 4,339,045 9,463,093 10,655,299 NET INCOME 10,027,846 16,283,053 29,629,176 39,231,126 NON-CONTROLLING INTEREST (651) 0 118,866 0 NET INCOME ATTRIBUTE TO CONTROLLING INTEREST 10,027,195 16,283,053 29,748,042 39,231,126 OTHER COMPREHENSIVE INCOME Foreign currency translation gain, net of tax 142,118 646,405 655,400 15,743,396 OTHER COMPREHENSIVE INCOME, NET OF TAX 142,118 646,405 655,400 15,743,396 COMPREHENSIVE INCOME $10,169,313 $16,929,458 30,403,442 $54,974,522 NET INCOME PER COMMON SHARE BASIC $0.13 $0.22 0.40 $0.51 DILUTED $0.13 $0.21 0.39 $0.50 WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING BASIC 74,636,155 75,101,869 74,592,447 77,164,602 DILUTED 88,868,828 85,417,62
'/>"/>
SOURCE American Oriental Bioengineering, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
3. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
4. Aspirin Named 8th World Wonder by Majority of Americans
5. MedImmunes Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
6. American Heart Association Comment Saving Lives in Type 2 Diabetics: Could It Be as Easy as Lowering Blood Pressure?
7. TrialCheck(R) Cancer Clinical Trial Matching Interface to Debut on American Cancer Society Web Site
8. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
9. Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting
10. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
11. New MIRCERA(R) Data Analyses to be Featured at the American Society of Nephrology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... and TARRYTOWN, N.Y. , May ... SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced ... published online the positive Phase 2a study results of ... is an investigational monoclonal antibody targeting the alpha subunit ... signaling of both IL-4 and IL-13, drivers of Th2 ...
(Date:5/21/2013)... UNION CITY, Calif. , May 21, 2013 /PRNewswire/ ... manufacturing point-of-care blood analysis systems, announced today that ... will present at the Stifel Annual Dental & Veterinary ... ET. The conference will be held at Le Parker ... . About Abaxis Abaxis develops, ...
(Date:5/21/2013)... May 21, 2013 Reportlinker.com announces ... available in its catalogue:   ... Scenario for Medical Devices in the US ...   Changing Regulatory and Reimbursement ... Market   Summary ...
Breaking Medicine Technology:Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 3Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 4
... HIGHLIGHTS:2011 Results (all percentages are to ... reported sales increased 11% to $626 million. Q3 sales grew ... sales growing organically by 4% and 2%, respectively.  Recently completed ... exchange rates contributed an additional 5% to reported sales growth ...
... Botanic Pharmaceutical Inc. (NYSE AMEX: CBP ) ... distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ... recently hosted a technical exchange between 13 senior research ... and herbal medicine. China Botanic participated ...
Cached Medicine Technology:Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 2Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 3Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 4Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 5Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 6Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 7Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 8Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 9Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 10Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 11Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 12Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 13China Botanic Hosts Technical Exchange for Industry Research Experts 2China Botanic Hosts Technical Exchange for Industry Research Experts 3
(Date:5/21/2013)... 2013 Standard advice for mattress shoppers ... else. However given industry’s less than exceptional satisfaction ratings ... the internet, Consumer Mattress Reports sets out to revise ... Best Mattress .” , This article addresses several components ... that may not be readily apparent to many shoppers. ...
(Date:5/21/2013)... 2013 DISCcert has served the training ... use 17 DISC applications at the July 25 & ... , The July 25 & 26th DISC certification in ... of applying DISC. The time-tested, proven support materials will ... DISC training materials ; worksheets, handouts, learning ...
(Date:5/21/2013)... 2013 Parker Waichman LLP, a national ... injured by defective medical devices, is addressing new research ... on May 15, 2013. The study found that magnetic ... that occur in patients with metal-on-metal hip implants even ... ) , “We’ve known for quite ...
(Date:5/21/2013)... France: The Orsiro stent, which is a novel ... demonstrated non-inferiority to the Xience Prime everolimus-eluting stent ... lumen loss at nine months in the results ... today. , The BIOFLOW-II substudy used intravascular ultrasound ... assess neointimal hyperplasia and stent apposition at nine ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Phoseon Technology ... at the 20th Annual IMI European Ink Jet ... proven market leader, Phoseon continues to invest in product ... the adoption of UV LED curing in printing applications. ... families on the market offering both air cooled and ...
Breaking Medicine News(10 mins):Health News:Choosing the Best Mattress Simplified in Consumer Mattress Reports’ Latest Article 2Health News:DISCcert Offers 17 Applications in Coming DISC Certification 2Health News:DISCcert Offers 17 Applications in Coming DISC Certification 3Health News:DISCcert Offers 17 Applications in Coming DISC Certification 4Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 2Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 3Health News:Biodegradable stent proves non-inferior to drug-eluting stent 2
... International Liver Congress 2009, the 44th annual meeting of the ... Journalist registrations are being accepted for International Liver Congress 2009, ... , Press registration is free of charge for all holders ... The official EASL press conference will be held from 13.15 ...
... A failing heart makes a lot of a hormone needed ... but not enough of the enzyme needed to activate it, ... College of Georgia researchers found people in heart failure have ... pro-atrial natriuretic peptide, a hormone made by heart muscle cells ...
... WASHINGTON, March 31 Jeffrey Levi, Ph.D., ... today before the U.S. House Energy and Commerce Committee,s ... Care Work for American Families: Protecting the Public Health." ... investing in prevention, and the importance of incorporating public ...
... March 31 The not-for-profit LENA Foundation ... Biennial Meeting of the Society of Research in Child ... Colorado, four talks and one poster will be presented ... http://www.newscom.com/cgi-bin/prnh/20090210/LA69114 )"This year,s SRCD is a great opportunity ...
... 31 /PRNewswire-FirstCall/ - Hard To Treat Diseases (HTDS) ... Award" is a most coveted, prestigious award, and ... Science and Technological Development. Submitted with the award ... preliminary trial of their Ribavirin product, confirming its ...
... March 31 Five local organizations and,individuals committed ... cholesterol,in Hispanic communities were awarded 2009 Cheerios Angel ... Chosen from a winning pool of nominations, ... healthier lifestyles and provided excellent resources to help ...
Cached Medicine News:Health News:New tests provide new insight into why patients are in heart failure 2Health News:New tests provide new insight into why patients are in heart failure 3Health News:Trust for America's Health Testifies before Congress on Building Prevention into Health Reform 2Health News:Trust for America's Health Testifies before Congress on Building Prevention into Health Reform 3Health News:Trust for America's Health Testifies before Congress on Building Prevention into Health Reform 4Health News:Five Research Studies at International SRCD Meeting in Denver Use Technology from Boulder Foundation 2Health News:Five Research Studies at International SRCD Meeting in Denver Use Technology from Boulder Foundation 3Health News:Hard To Treat Diseases (HTDS) Best Technological Innovation Award 2009 2Health News:Cheerios(R) Angel de mi Corazon Awards $25,000 to Those Who Fight Heart Disease and High Cholesterol in Hispanic Communities Across the U.S. 2Health News:Cheerios(R) Angel de mi Corazon Awards $25,000 to Those Who Fight Heart Disease and High Cholesterol in Hispanic Communities Across the U.S. 3Health News:Cheerios(R) Angel de mi Corazon Awards $25,000 to Those Who Fight Heart Disease and High Cholesterol in Hispanic Communities Across the U.S. 4
A gentle yet highly effective corneal rust ring remover with Alger brush of 1mm burr. Runs off 1 x AA battery, no switches, simply spin mandrel to operate....
Foreign body removal system. Designed to aid in the removal of foreign bodies and corneal rust rings....
Foreign body removal system. Designed to aid in the removal of foreign bodies and corneal rust rings. Ophtho-burr handpiece only. Battery powered handpiece....
Katena ophthalmic burr for polishing pterygiums, includes one round diamond burr and has an storage case....
Medicine Products: